EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

High-density lipoproteins in diabetic kidney disease: are they always renoprotective? Literature review

V. A. Chernyshov

Ukrainian Therapeutical Journal · 31.03.2026 · (1) · 50-61

DOI: 10.30978/utj2026-1-50 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ukrainian Therapeutical Journal, online erschienen am 31.03.2026. Verfasst von V. A. Chernyshov. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The review is devoted to an actual controversial issue of direct influence of high‑density lipoprotein cholesterol (HDL‑C) on chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM) that remains unclear due to limitation of existing data base. Low HDL‑C is a recognized risk factor (RF) for diabetic kidney disease (DKD) that is considered the most significant microvascular complication of DM that affects 40 — 50% of patients with T2DM. A U‑shaped association has been established between HDL‑C and the outcomes of chronic kidney disease. This means that an increase in HDL‑C to a proper level can be renoprotective, and exceeding this level can lead to adverse outcomes due to a loss of HDL particles’ renoprotective properties. The intricate relationship between HDL‑C and clinical outcomes, including end‑stage renal disease and all‑cause mortality, among patients with T2DM and CKD requires further investigation to verify the influence of the HDL particle fractional compound on the progression of DKD. Contemporary opinions about structure and function of HDL in lipid metabolism, their anti‑diabetic and renal protective properties, changes in structure and function of HDL particles in DKD are given in the review. The data presented here examine the relationship between the consequences of DKD and HDL‑C levels and address the question of which serum HDL‑C concentration is associated with renoprotection and which is associated with a loss of HDL particles’ ability to prevent the progression of DKD. It’s emphasized that treatment of the early stages of DKD can significantly delay the onset of end‑stage renal disease. The search for biological predictors and risk factors for chronic kidney disease (CKD) is therefore ongoing, which will facilitate the early identification of high‑risk patients and the development of effective strategies for preventing diabetic complications and slowing the progression of kidney damage. Modern medications which are able to increase both HDL‑C and apolipoprotein A‑I known as a main apoliprotein component of HDL particles can prevent complications or promote a reversion of DM due to their anti‑diabetic properties. It has been emphasised that elucidating the mechanisms of action of these drugs will make it possible to optimise treatment, in particular by improving the function of HDL particles rather than their concentration in serum in DKD. Anti‑diabetic and vascular protective action of HDL is a reason to expect that improvement of HDL particle function will give a significant result in prevention of DKD and other microvascular diabetic complications as well as in treatment of chronic hyperglycemic state. Particular attention has been paid to improving the pharmacological modulation of HDL particles, aimed at their functional optimisation through molecular engineering interventions in their structure and, consequently, the properties of the modified particles, which can transport drugs to target organs, which is more beneficial than increasing HDL levels.

Zitieren

APA

Chernyshov, V. A. (2026). High-density lipoproteins in diabetic kidney disease: are they always renoprotective? Literature review. Ukrainian Therapeutical Journal, 50-61. https://doi.org/10.30978/utj2026-1-50

Vancouver

Chernyshov VA. High-density lipoproteins in diabetic kidney disease: are they always renoprotective? Literature review. Ukrainian Therapeutical Journal. 2026:50-61. doi:10.30978/utj2026-1-50

BibTeX
@article{Chernyshov2026,
  author = {Chernyshov, V. A.},
  title = {High-density lipoproteins in diabetic kidney disease: are they always renoprotective? Literature review},
  journal = {Ukrainian Therapeutical Journal},
  year = {2026},
  number = {1},
  pages = {50--61},
  doi = {10.30978/utj2026-1-50}
}
Kostenlos starten →